Skip Navigation


Human Molecular Genetics Advance Access originally published online on September 14, 2004
Human Molecular Genetics 2004 13(21):2607-2612; doi:10.1093/hmg/ddh293
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
13/21/2607    most recent
ddh293v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by de Yebra, L.
Right arrow Articles by Mahy, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Yebra, L.
Right arrow Articles by Mahy, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, Vol. 13, No. 21 © Oxford University Press 2004; all rights reserved

Reduced KIAA0471 mRNA expression in Alzheimer's patients: a new candidate gene product linked to the disease?

Lluïsa de Yebra1,*, Rosa Adroer1, Nuria de Gregorio-Rocasolano2, Rafael Blesa3, Ramon Trullas2 and Nicole Mahy1

1Unitat de Bioquímica, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Facultat de Medicina, Universitat de Barcelona, C/Casanova 143, 08036 Barcelona, Spain, 2Unitat de Neurobiologia, Institut d'Investigacions Biomèdiques de Barcelona, CSIC, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C/Rosselló 161, 08036 Barcelona, Spain and 3Servei de Neurologia, Hospital de la Santa Creu i Sant Pau, C/St. Antoni M. Claret 167, 08025 Barcelona, Spain

Received May 13, 2004; Revised July 6, 2004; Accepted September 4, 2004

Alzheimer's disease (AD) phenotype complexity raises the question whether genetic features remain unknown. Although a few percentage of patients are familial cases linked to mutations in amyloid precursor protein, presenilin 1 or presenilin 2 genes, the remainder are considered mainly sporadic late-onset cases with a complex etiology. However, changes in gene expression or other genetic features of the individual can clearly contribute to develop the illness. Consequently, in this paper we have focused on the identification of new genes, the expression of which is altered in AD. We used the technique of differential display reverse transcriptase–polymerase chain reaction (DDRT–PCR) in order to study the gene expression differences in brain tissue from patients in an advanced stage of AD. After studying medial septum and hippocampus brain areas, we found an inhibition of the KIAA0471 gene expression in three out of six AD patients, including one with a presenilin 1 gene mutation. This gene encodes for a large protein that presents, in its predicted form, 95% homology with IDN4-GGTR sequences. These results may provide significant clues for understanding the molecular mechanisms underlying septohippocampal neurodegeneration. In addition, they may open a new area of research for diagnostic and therapeutic tools, the relevance of which is also considered.

* To whom correspondence should be addressed. Tel: +34 934024525; Fax: +34 934035882; Email: lluisadeyebra{at}ub.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.